Bracco introduces new colon insufflator for cancer detection

27 March 2017 (Last Updated March 27th, 2017 18:30)

Bracco Imaging's US subsidiary Bracco Diagnostics has introduced new colon insufflator PROTOCO2L TOUCH to aid the detection of colon cancer.

Bracco Imaging's US subsidiary Bracco Diagnostics has introduced new colon insufflator PROTOCO2L TOUCH to aid the detection of colon cancer.

The new device is designed to inflate the colon with carbon dioxide (CO2) during the diagnosis procedure called computed tomography (CT) colonography (CTC) performed for colon cancer patients.

It is used in CTC exams or virtual colonoscopy to achieve optical distension of the colon.

"CTC offers clinicians and patients a fast and reliable screening test with an added benefit for patients in that they do not need to undergo sedation."

Bracco Group Global Medical and Regulatory Affairs senior vice-president Alberto Spinazzi said: "Colorectal cancer is one of the deadliest cancers, but has a 90% cure rate when detected early.

"CTC offers clinicians and patients a fast and reliable screening test with an added benefit for patients in that they do not need to undergo sedation.

"This means that a patient does not need to have someone else drive them to and from their CTC exam, and the patient does not need to take a day away from their work."

The  insufflator uses automated insufflation of CO2  which is said to be more rapidly absorbed with less post-procedural discomfort when compared to room air.

The device also includes features such as touch screen and digital technology to offer procedural efficiency as well as small tip for patient comfort and safety measures to prevent over-insufflation.

The PROTOCO2L TOUCH provides a software controlled administration and regulation of CO2.

It aids in decreasing the staff time during the process of colon insufflation, increases productivity, facilitates adequate and consistent distension in a patient and operator-independent manner.